Oct 17 (Reuters) - Drugmaker AstraZeneca Plc said on
Thursday its experimental breast cancer treatment will get a
speedy review by the U.S. Food and Drug Administration, with a
decision by the health regulator expected in the second quarter
of next year.
The British company in March agreed to pay up to $6.9
billion to work with Japan's Daiichi Sankyo Co Ltd on
the treatment, trastuzumab deruxtecan or also known as DS-8201,
in a direct challenge to the world's biggest cancer drug maker
Roche Holding AG.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard
Orr)
Astrazeneca (AZN)
